Calabro Rocco S, Gervasi Giuseppe, Bramanti Placido, Cavallini Anna
IRCCS Centro Neurolesi Bonino- Pulejo, Messina, Italy.
Recent Pat Cardiovasc Drug Discov. 2012 Apr;7(1):42-52. doi: 10.2174/157489012799362412.
Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.
中风是西方国家第三大主要死因和永久性残疾的主要原因。症状发作后3小时内进行再灌注是急性缺血性中风所有治疗策略中最有益的。阿替普酶是首个获美国食品药品监督管理局批准的溶栓治疗药物。然而,其使用仍局限于特定患者亚组,且可能伴有严重副作用,包括大面积脑出血。本综述旨在研究缺血性中风的当前和未来治疗策略,包括新型纤溶药物、超声溶栓、机械取栓及近期专利。